Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
19.71 (1y: +7%)
Market Cap 552.42 M P/E(ttm) 518.70
Enterprise Value 481.44 M P/B 4.20
SGNT- NAS (USA)
Sagent Pharmaceuticals Co
Not Rated
Top Ranked Predictable Companies
$19.71
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
SGNT's Cash to Debt is ranked higher than
84% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SGNT: No Debt )
SGNT' s 10-Year Cash to Debt Range
Min: 1.66   Max: No Debt
Current: No Debt
Equity to Asset 0.765
SGNT's Equity to Asset is ranked higher than
80% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SGNT: 0.765 )
SGNT' s 10-Year Equity to Asset Range
Min: -1.15   Max: 0.77
Current: 0.77
-1.15
0.77
F-Score: 5
Z-Score: 8.31
M-Score: -2.7
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -8.40
SGNT's Operating margin (%) is ranked lower than
60% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. SGNT: -8.40 )
SGNT' s 10-Year Operating margin (%) Range
Min: -258.1   Max: -8.4
Current: -8.4
-258.1
-8.4
Net-margin (%) -9.2
SGNT's Net-margin (%) is ranked lower than
61% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SGNT: -9.2 )
SGNT' s 10-Year Net-margin (%) Range
Min: -253.7   Max: -9.2
Current: -9.2
-253.7
-9.2
ROE (%) -12.8
SGNT's ROE (%) is ranked lower than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. SGNT: -12.8 )
SGNT' s 10-Year ROE (%) Range
Min: -40.2   Max: -12.8
Current: -12.8
-40.2
-12.8
ROA (%) -9.8
SGNT's ROA (%) is ranked lower than
62% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. SGNT: -9.8 )
SGNT' s 10-Year ROA (%) Range
Min: -59.7   Max: -9.8
Current: -9.8
-59.7
-9.8
ROC (Joel Greenblatt) (%) -35.80
SGNT's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. SGNT: -35.80 )
SGNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -221   Max: -35.8
Current: -35.8
-221
-35.8
ยป SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q3 2011

SGNT Guru Trades in Q3 2011

Steven Cohen Sold Out
» More
Q3 2012

SGNT Guru Trades in Q3 2012

Steven Cohen 300 sh (New)
» More
Q4 2012

SGNT Guru Trades in Q4 2012

Steven Cohen 300 sh (unchged)
» More
Q1 2013

SGNT Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGNT



No Insider Trades Found!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 518.70
SGNT's P/E(ttm) is ranked lower than
69% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.30 vs. SGNT: 518.70 )
SGNT' s 10-Year P/E(ttm) Range
Min: 428.42   Max: 521.05
Current: 518.7
428.42
521.05
P/B 4.20
SGNT's P/B is ranked lower than
51% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. SGNT: 4.20 )
SGNT' s 10-Year P/B Range
Min: 2.78   Max: 4.79
Current: 4.2
2.78
4.79
P/S 2.70
SGNT's P/S is ranked higher than
64% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. SGNT: 2.70 )
SGNT' s 10-Year P/S Range
Min: 1.09   Max: 3.44
Current: 2.7
1.09
3.44
PFCF 75.80
SGNT's PFCF is ranked higher than
51% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. SGNT: 75.80 )
SGNT' s 10-Year PFCF Range
Min: 62.62   Max: 76.15
Current: 75.8
62.62
76.15
EV-to-EBIT 333.3
SGNT's EV-to-EBIT is ranked lower than
68% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. SGNT: 333.3 )
SGNT' s 10-Year EV-to-EBIT Range
Min: 295   Max: 370.1
Current: 333.3
295
370.1

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 23.2
SGNT's Price/Net Cash is ranked lower than
57% of the 184 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. SGNT: 23.2 )
SGNT' s 10-Year Price/Net Cash Range
Min: 11.4   Max: 18.9
Current: 23.2
11.4
18.9
Price/Net Current Asset Value 11.3
SGNT's Price/Net Current Asset Value is ranked higher than
72% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. SGNT: 11.3 )
SGNT' s 10-Year Price/Net Current Asset Value Range
Min: 9.1   Max: 9.1
Current: 11.3
Price/Tangible Book 4.4
SGNT's Price/Tangible Book is ranked higher than
51% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGNT: 4.4 )
SGNT' s 10-Year Price/Tangible Book Range
Min: 3.1   Max: 3.5
Current: 4.4
3.1
3.5
Price/Median PS Value 1.2
SGNT's Price/Median PS Value is ranked higher than
52% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SGNT: 1.2 )
SGNT' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.1
Current: 1.2
0.5
1.1
Earnings Yield (Greenblatt) 0.30
SGNT's Earnings Yield (Greenblatt) is ranked lower than
51% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SGNT: 0.30 )
SGNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 0.3
Current: 0.3

Business Description

Sagent Holding Co was originally incorporated as a Cayman Islands company in 2006. The company is an injectable pharmaceutical company that develops and sources products which they sell primarily in the U.S. through its sales and marketing team. With a primary focus on generic injectable pharmaceuticals, the company offer its customers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and seek to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. The company's key critical care products include: Adenosine: Adenosine is an antiarrhythmic commonly used in the treatment of cardiac rhythm disturbances in critical care situations. Adenosine is the generic equivalent of Astellas Pharma U.S., Inc.'s ("Astellas") Adenocard; Heparin: Heparin is a vital anticoagulant used to prevent and treat blood clotting, especially during and after surgery and dialysis. Two of their business partners, A.C.S. Dobfar S.p.a. ("Dobfar") and Gland Pharma Limited ("Gland"), provided products that collectively accounted for approximately 59% and 14%, total net revenue for the year ended December 31, 2009 and approximately 53% and 25%, net revenue for the nine month period ended September 30, 2010. The company's' trademarks and service marks such as "Sagent Pharmaceuticals," "Sagent," "Injectables Excellence," "Discover Injectables Excellence," and "PreventIV Measures," which are protected under applicable intellectual property laws and are the property of Sagent Holding Co. or its subsidiaries. The company's competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical companies and generic drug companies. Its competitors include Baxter International Inc. ("Baxter"), Boehringer Ingelheim Group ("Boehringer"), Fresenius Kabi ("Fresenius"), a division of Fresenius SE, Hikma Pharmaceuticals PLC ("Hikma") (principally as a result of its pending acquisition of Baxter's generic injectable business), Hospira, Inc. ("Hospira"), Pfizer Inc. ("Pfizer"), Sandoz International GmbH ("Sandoz"), a division of Novartis AG, and Teva Pharmaceutical Industries Ltd. ("Teva").
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:
ยป More Articles for SGNT

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK